MediWound Announces $197 Million BARDA Contract Awarded to Vericel for NexoBrid procurement and Development

On April 2, 2026, MediWound Ltd. announced that its North American distributor, Vericel Corporation, was awarded a ten-year contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) valued at up to $197 million for NexoBrid. NexoBrid is an FDA-approved biological orphan drug used for the enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns. The contract includes a base period of $35 million, with approximately $10 million allocated over the next 12 months for initial procurement for the U.S. Strategic National Stockpile and the establishment of a Vendor Managed Inventory system. Beyond procurement, the contract funds the design and validation of a U.S.-based manufacturing facility, the development of a room-temperature stable formulation, and clinical activities for a potential expanded indication for blast trauma injuries. This long-term agreement strengthens the commercial and strategic positioning of NexoBrid in the U.S. market through 2036.